Vabicaserin HCl; Vabicaserin hydrochloride

• CAT Number: I009975
• CAS Number: 887258-94-8
• Molecular Formula: C15H21ClN2
• Molecular Weight: 264.797
• Purity: ≥95%
• Solubility: Soluble in DMSO
• Storage: 0 - 4 °C for short term, or -20 °C for long term
• InChI: InChI=1S/C15H20N2.ClH/c1-3-11-9-16-7-8-17-10-12-4-2-5-13(12)14(6-1)15(11)17;/h1,3,6,12-13,16H,2,4-5,7-10H2;1H/t12-,13-;/m0./s1
• InChIKey: PYPPENBDXAWXJC-QNTKWALQSA-N
• SMILES: C1CC2CN3CCNCC4=C3C(=CC=C4)C2C1.Cl

Vabicaserin HCl (CAT: I009975) is a selective agonist of the 5-HT2C (5-hydroxytryptamine 2C) receptor, a subtype of serotonin receptors. It has shown potential for the treatment of schizophrenia, a complex psychiatric disorder characterized by altered perception, cognition, and behavior. By activating the 5-HT2C receptors, vabicaserin HCl modulates the neurotransmitter serotonin in the brain, which is believed to play a role in regulating mood and cognition. The specific mechanism of action of vabicaserin HCl in treating schizophrenia is not fully understood, but its selective activity on the 5-HT2C receptors suggests it may have an impact on the underlying neurobiology of the disorder.

Reference

1:Shen JH, Zhao Y, Rosenzweig-Lipson S, Popp D, Williams JB, Giller E, Detke MJ, Kane JM. A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia. J Psychiatr Res. 2014 Jun;53:14-22. doi: 10.1016/j.jpsychires.2014.02.012. PubMed PMID: 24613032.
2: Tong Z, Chandrasekaran A, DeMaio W, Jordan R, Li H, Moore R, Poola N, Burghart P, Hultin T, Scatina J. Species differences in the formation of vabicaserin carbamoyl glucuronide. Drug Metab Dispos. 2010 Apr;38(4):581-90. doi: 10.1124/dmd.109.028639. PubMed PMID: 20032194.
3:Tong Z, Chandrasekaran A, DeMaio W, Espina R, Lu W, Jordan R, Scatina J. Metabolism of vabicaserin in mice, rats, dogs, monkeys, and humans. Drug Metab Dispos. 2010 Dec;38(12):2266-77. doi: 10.1124/dmd.110.033670. PubMed PMID: 20739639.